The present study enriches existing research by meticulously comparing neutralizing antibody responses to specific SARS-CoV-2 variants in IBD patients undergoing different treatments—anti-TNF therapy, non-anti-TNF biologics, no therapy, or mesalamine—alongside a control group. The gene discussed is TNF; the disease is inflammatory bowel disease.